The FDA approved a Phase 2b trial of CS1, a new PAH therapy being tested for its impact on lung vessel resistance and ...

People with CTEPH and higher PAWP may see fewer gains from BPA, though safety and survival remain similar, a study shows.

People with CTEPH and higher PAWP may see fewer gains from BPA, though safety and survival remain similar, a study shows.

Scientists found altered activity of the PUM1 protein plays a key role in pulmonary hypertension development, making it a PH ...

Tiakis Biotech is preparing for a Phase 2 U.S. trial of tiprelestat for PAH after completing a data package required for ...

This holiday season, columnist Anna Jeter is searching for some silver linings in her life and to try to be grateful, despite ...

What is Letairis for pulmonary arterial hypertension? Letairis (ambrisentan) is an oral therapy approved to improve exercise ability and delay clinical worsening or disease progression in adults with ...

No description.Get Your Glow On! The nation’s only “Glow Climb” celebrating the 20th Anniversary Fight For Air Climb - San Francisco. This iconic San Francisco landmark features 1,197 steps from the ...

No description.Louisville's Only Stair-Climbing Event Supporting Clean Air & Lung Health. This iconic Louisville landmark features 1,191 steps from the ground floor to the top floor. Take it fast or ...

The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American ...

What is Veletri for pulmonary arterial hypertension? Veletri (epoprostenol) is an intravenous (into-the-vein) infusion therapy approved to improve exercise capacity in people with pulmonary arterial ...